Aspire Biopharma Holdings (ASBP) FCF Margin (2025 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly FCF Margin came in at 3352.68% in Q2 2026, up 68.72% quarter-over-quarter from 10716.76% in Q1 2026.
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) FCF Margin (2025 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported FCF Margin for 2 consecutive years, with 3352.68% the latest figure, recorded in Q2 2026.
- On a quarterly basis, FCF Margin changed N/A year-over-year to 3352.68% in Q2 2026; TTM through Jun 2026 was 7358.1%, a N/A change from a year earlier, with the FY2025 full-year figure at 79385.49%, changed N/A from the prior year.
- FCF Margin was 3352.68% for Q2 2026 at Aspire Biopharma Holdings, up from 10716.76% in the prior quarter.
- Over five years, FCF Margin peaked at 3352.68% in Q2 2026 and troughed at 56868.06% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 13.35% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -388.28% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -18,629.40% |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 | -3,352.68% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3,352.68% |
| Mar 31, 2026 | -10,716.76% |
| Dec 31, 2025 | -21,775.19% |
| Sep 30, 2025 | -56,868.06% |